Blair William & Co. IL Sells 4,563 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Blair William & Co. IL lessened its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 3.9% in the first quarter, Holdings Channel.com reports. The firm owned 111,475 shares of the biotechnology company’s stock after selling 4,563 shares during the period. Blair William & Co. IL’s holdings in Rocket Pharmaceuticals were worth $744,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. increased its holdings in Rocket Pharmaceuticals by 4.1% during the 4th quarter. Envestnet Asset Management Inc. now owns 32,422 shares of the biotechnology company’s stock worth $408,000 after purchasing an additional 1,280 shares in the last quarter. Virtus ETF Advisers LLC boosted its stake in shares of Rocket Pharmaceuticals by 40.4% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,656 shares of the biotechnology company’s stock worth $71,000 after buying an additional 1,628 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of Rocket Pharmaceuticals by 16.1% during the 1st quarter. Victory Capital Management Inc. now owns 11,929 shares of the biotechnology company’s stock worth $80,000 after buying an additional 1,658 shares during the last quarter. Covestor Ltd boosted its stake in shares of Rocket Pharmaceuticals by 33,166.7% during the 4th quarter. Covestor Ltd now owns 1,996 shares of the biotechnology company’s stock worth $25,000 after buying an additional 1,990 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Rocket Pharmaceuticals by 10.7% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 21,388 shares of the biotechnology company’s stock worth $143,000 after buying an additional 2,059 shares during the last quarter. Institutional investors own 98.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on RCKT shares. Morgan Stanley restated an “equal weight” rating and set a $7.00 price objective on shares of Rocket Pharmaceuticals in a research note on Wednesday, May 28th. Cantor Fitzgerald reduced their price objective on shares of Rocket Pharmaceuticals from $10.00 to $8.00 and set an “overweight” rating for the company in a research note on Friday. Jefferies Financial Group restated a “hold” rating on shares of Rocket Pharmaceuticals in a research note on Wednesday, May 28th. Wedbush reiterated an “outperform” rating and issued a $32.00 target price on shares of Rocket Pharmaceuticals in a research note on Friday, May 16th. Finally, UBS Group cut their target price on shares of Rocket Pharmaceuticals from $12.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, June 17th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $16.40.

Rocket Pharmaceuticals Stock Down 7.4%

Shares of RCKT opened at $2.86 on Monday. The firm’s 50 day moving average is $2.95 and its 200-day moving average is $6.11. The stock has a market capitalization of $308.59 million, a PE ratio of -1.14 and a beta of 0.65. The company has a current ratio of 9.19, a quick ratio of 9.19 and a debt-to-equity ratio of 0.05. Rocket Pharmaceuticals, Inc. has a 12 month low of $2.19 and a 12 month high of $22.01.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.02). During the same quarter last year, the company earned ($0.74) EPS. Equities research analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current year.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.